WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 562360
CAS#: VLX600 HCl
Description: VLX600 is a cell-permeable anticancer agent. It acts by reducing mitochondrial oxidative phosphorylation in tumor cells.
MedKoo Cat#: 562360
Name: VLX600 HCl
CAS#: VLX600 HCl
Chemical Formula: C17H16ClN7
Exact Mass: 317.1389
Molecular Weight: 353.814
Elemental Analysis: C, 57.71; H, 4.56; Cl, 10.02; N, 27.71
Related CAS #: 327031-55-0 (free base) 1622945-04-3 (free base) VLX600 HCl
Synonym: VLX600; VLX600; VLX600; OxPhos Inhibitor; VLX600 HCl; VLX600 hydrohloride;
IUPAC/Chemical Name: 6-Methyl-3-((2Z)-2-(1-(2-pyridinyl)ethylidene)hydrazino)-5H-[1,2,4]triazino[5,6-b]indole hydrochloride
InChi Key: LFXBMCFIVGRMHK-KELDOBJCSA-N
InChi Code: InChI=1S/C17H15N7.ClH/c1-10-6-5-7-12-14(10)19-16-15(12)22-24-17(20-16)23-21-11(2)13-8-3-4-9-18-13;/h3-9H,1-2H3,(H2,19,20,23,24);1H/b21-11-;
SMILES Code: C/C(C1=NC=CC=C1)=N/NC2=NN=C3C(NC4=C3C=CC=C4C)=N2.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 353.814 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Vitiello GA, Medina BD, Zeng S, Bowler TG, Zhang JQ, Loo JK, Param NJ, Liu M, Moral AJ, Zhao JN, Rossi F, Antonescu CR, Balachandran VP, Cross JR, DeMatteo RP. Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor. Clin Cancer Res. 2018 Feb 15;24(4):972-984. doi: 10.1158/1078-0432.CCR-17-2697. Epub 2017 Dec 15. PubMed PMID: 29246941; PubMed Central PMCID: PMC5815929.
2: Zhang X, Mofers A, Hydbring P, Olofsson MH, Guo J, Linder S, D'Arcy P. MYC is downregulated by a mitochondrial checkpoint mechanism. Oncotarget. 2017 Oct 6;8(52):90225-90237. doi: 10.18632/oncotarget.21653. eCollection 2017 Oct 27. PubMed PMID: 29163823; PubMed Central PMCID: PMC5685744.
3: Fryknäs M, Zhang X, Bremberg U, Senkowski W, Olofsson MH, Brandt P, Persson I, D'Arcy P, Gullbo J, Nygren P, Schughart LK, Linder S, Larsson R. Iron chelators target both proliferating and quiescent cancer cells. Sci Rep. 2016 Dec 7;6:38343. doi: 10.1038/srep38343. PubMed PMID: 27924826; PubMed Central PMCID: PMC5141479.
4: Urra FA, Weiss-López B, Araya-Maturana R. Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells. Curr Pharm Des. 2016;22(39):5998-6008. Review. PubMed PMID: 27510477.
5: Wang L, Zhao S, Bao G, Zhang Y, Xi S, Zhou G, Zhai X, Gong P. Design, Synthesis, and Cytotoxicity of Novel 2,4,6-Trisubstituted 1,3,5- triazines Bearing Aryl Hydrazone Moiety as Potent Antitumor Agent. Med Chem. 2016;12(7):621-630. PubMed PMID: 26732116.
6: Zhang X, Fryknäs M, Hernlund E, Fayad W, De Milito A, Olofsson MH, Gogvadze V, Dang L, Påhlman S, Schughart LA, Rickardson L, D'Arcy P, Gullbo J, Nygren P, Larsson R, Linder S. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat Commun. 2014;5:3295. doi: 10.1038/ncomms4295. PubMed PMID: 24548894; PubMed Central PMCID: PMC3929804.
